The MarketReader Minute
💊Moderna Slashes R&D by $1.1B Amid Revenue Miss, Summit Soars on Capital Raise, and Gilead Reports Breakthrough in HIV Prevention | Biotech Sector Insights
Moderna Inc. (MRNA), which dropped sharply after announcing a strategic shift to reduce R&D expenses and forecasting lower revenue for 2025. Biogen has recently appointed two new board members to enhance its governance.